Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease with limited treatment options. Up to 40% of patients with IBD fail to respond to conventional therapies, partly due to our limited understanding of the cells that form the large intestine, but also how they change in in patients affected by this disease.

The study published today by the group of Professor Alison Simmons at the MRC Human Immunology Unit paves the way for better treatments for IBD by providing the first detailed single cell resolution analysis of colon cells in health and disease.

Read the full article

Similar stories

New insights into cellular pH regulators could inform research into neurological disease and cancer

High-resolution structures of two proteins that regulate acidity inside cells reveal how they interact with ions and membrane lipids, providing new insights into their roles in disease and potential avenues for drug discovery.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

MORU’s contribution to ASEAN health highlighted during The Princess Royal’s Thailand visit

The visit highlighted MORU’s longstanding contribution to health across Thailand and the wider ASEAN region, and the value of collaboration between Mahidol University and Oxford's Nuffield Department of Medicine.

Patient enrolment begins in PARTNERS trial to identify the first effective treatments for Bundibugyo virus disease

Patient enrolment has begun in the Democratic Republic of the Congo for the PARTNERS clinical trial of treatments for Bundibugyo virus disease (BVD). The trial is led in the DRC by the Institute National pour la Recherche Biomedicale, supported by the Institute of Tropical Medicine in Belgium, Ministry of Public Health of the Democratic Republic of the Congo, ALIMA (The Alliance for International Medical Action) and outbreak response teams from Médecins Sans Frontières (MSF). International trial coordination is led by the Pandemic Sciences Institute at the University of Oxford.

Professor Le Van Tan appointed Interim Director of OUCRU Ho Chi Minh City

We are pleased to announce that Professor Lê Văn Tấn has been appointed Interim Director of OUCRU Ho Chi Minh City, with effect from 24 June.